Coronavirus channel feed

BAR­DA bets $483M on Mod­er­na’s Covid-19 vac­cine as the biotech plots ul­tra-fast PhI­II, re­cruit­ing 150 staffers to scale up 24/7

6 years ago
Deals

Covid-19 vac­cine track­er up­dat­ed to in­clude GSK/Sanofi col­lab­o­ra­tion

6 years ago
FDA+

Har­vard profs main­tain that the FDA's re­cent ac­tions on Covid-19 de­val­ue the gold stan­dard and threat­en pub­lic trust

6 years ago
FDA+

Covid-19 roundup: Blis­tered by heat­ed re­ac­tion to their role in the out­break, Bio­gen makes amends with Covid-19 'biobank’

6 years ago

FDA of­fers guid­ance for gener­ic drug de­vel­op­ers of hy­drox­y­chloro­quine, chloro­quine

6 years ago
FDA+

Gilead takes a hit af­ter a close­ly-watched Covid-19 tri­al of remde­sivir is qui­et­ly ter­mi­nat­ed, rais­ing fresh doubts

6 years ago
R&D

Covid-19 roundup: Trump is crit­i­cized for cut­ting off WHO fund­ing; J&J sets up TV show to chron­i­cle vac­cine de­vel­op­ment

6 years ago

As GSK and Sanofi promise to pro­duce a Covid-19 vac­cine at In­dy 500 speed, some ex­perts start to push back on time­lines

6 years ago
R&D

Johns Hop­kins re­searchers pub­lish a how-to guide­book on Covid-19 plas­ma trans­fu­sions

6 years ago

Covid-19 roundup: J&J charts swift path to 1B vac­cine dos­es; Em­bassy ca­ble spot­lights pos­si­ble Wuhan lab con­nec­tion to coro­n­avirus

6 years ago

Mod­er­na's mis­sion to spear­head a rev­o­lu­tion in vac­cine R&D comes cen­ter stage to­day as the world faces a cru­cial turn­ing point

6 years ago
R&D

FDA re­ports more short­ages of drugs used to put Covid-19 pa­tients on ven­ti­la­tors

6 years ago
FDA+

Cre­ative or un­eth­i­cal? Re­searchers’ Covid-19 Go­FundMe cam­paign spurs crit­ics

6 years ago
R&D
In Focus

Covid-19 roundup: Tri­al of Trump's fa­vorite Covid-19 drug nixed on ear­ly death risk; Is An­tho­ny Fau­ci on thin ice with the pres­i­dent?

6 years ago

A small remde­sivir study with lots of short­com­ings sug­gests it may be work­ing against Covid-19 — and 1 an­a­lyst fore­casts mid-May roll­out

6 years ago
R&D

Nat­ur­al killers are com­ing for Covid-19 and the ther­a­py, ex­perts say, could make things worse

6 years ago
R&D
In Focus

Covid-19 Track­er up­dates vac­cine can­di­dates

6 years ago
FDA+

Covid-19 roundup: Pfiz­er hus­tling up mil­lions of dos­es of vac­cine — de­tails $748M BioN­Tech deal; CDC tweaks stance on con­tro­ver­sial malar­ia drugs

6 years ago

Did Gilead just low­er the bar on cru­cial remde­sivir tri­als for Covid-19? Switch­ing end­points, amp­ing up tri­al size stir an­a­lyst­s' fears — and hopes

6 years ago
R&D

Weath­er­ing the storm: An­oth­er biotech braves Covid-19 in up­sized IPO

6 years ago
Financing
Startups

Covid-19 roundup: EU‘s top sci­en­tist re­signs in re­buke to agency’s Covid re­sponse; J&J posts neg­a­tive da­ta for its HIV drug

6 years ago

‘If grippe con­demns, the sec­ondary in­fec­tions ex­e­cute’: What the coro­n­avirus pan­dem­ic means for the field of an­tibi­otics

6 years ago
In Focus

Hos­pi­tals re­port ‘se­vere short­ages’ of Covid-19 tests, HHS sur­vey finds

6 years ago

Covid-19 roundup: Ex-FDA com­mish Got­tlieb joins Re­pub­li­can gov­er­nor's coro­n­avirus team; Phar­ma ap­proval rat­ings re­main in the toi­let

6 years ago
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times